A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

ID Number 14-0094

Principal Investigator(s)
William B Inabnet III

Department(s) or Division(s)
Hematology and Medical Oncology


The purpose of this study is to evaluate the safety and effectiveness of an experimental drug called seulmetinib, compared with a placebo (sugar pill). An experimental drug is not approved by the United States Food and Drug Administration (FDA) for use except in research studies.

Some patients will receive selumetinib (75 mg, orally twice daily) and some patients will receive a placebo (sugar pill). All patients will receive radioiodine treatment. You will not be able to choose what treatment you receive; it will be randomly selected by a computer.

Contact Information
Erin Bresnahan
(212) 824-7309

Recruiting Patients: Yes